Jasper Therapeutics Statistics Share Statistics Jasper Therapeutics has 15.02M
shares outstanding. The number of shares has increased by -99.12%
in one year.
Shares Outstanding 15.02M Shares Change (YoY) -99.12% Shares Change (QoQ) 0.14% Owned by Institutions (%) n/a Shares Floating 12.59M Failed to Deliver (FTD) Shares 360 FTD / Avg. Volume 5.43%
Short Selling Information The latest short interest is 12.68K, so 0% of the outstanding
shares have been sold short.
Short Interest 12.68K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 5.01
Valuation Ratios The PE ratio is -4.38 and the forward
PE ratio is null.
Jasper Therapeutics's PEG ratio is
0.21.
PE Ratio -4.38 Forward PE n/a PS Ratio 0 Forward PS 1.1 PB Ratio 5.06 P/FCF Ratio -4.94 PEG Ratio 0.21
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Jasper Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.98,
with a Debt / Equity ratio of 0.03.
Current Ratio 4.98 Quick Ratio 4.98 Debt / Equity 0.03 Debt / EBITDA -0.03 Debt / FCF -0.03 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.11M Employee Count 64 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -1.49M Effective Tax Rate 2.05%
Stock Price Statistics The stock price has increased by -52.38% in the
last 52 weeks. The beta is 2.73, so Jasper Therapeutics's
price volatility has been higher than the market average.
Beta 2.73 52-Week Price Change -52.38% 50-Day Moving Average 0.12 200-Day Moving Average 0.18 Relative Strength Index (RSI) 47.92 Average Volume (20 Days) 6,630
Income Statement
Revenue n/a Gross Profit n/a Operating Income -76.24M Net Income -71.27M EBITDA -71.39M EBIT -72.76M Earnings Per Share (EPS) -4.89
Full Income Statement Balance Sheet The company has 71.64M in cash and 1.81M in
debt, giving a net cash position of 69.82M.
Cash & Cash Equivalents 71.64M Total Debt 1.81M Net Cash 69.82M Retained Earnings -240.87M Total Assets 57.6M Working Capital 40.84M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -62.6M
and capital expenditures -552K, giving a free cash flow of -63.15M.
Operating Cash Flow -62.6M Capital Expenditures -552K Free Cash Flow -63.15M FCF Per Share -4.33
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
